GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Clarus Therapeutics Holdings Inc (OTCPK:CRXTQ) » Definitions » ROIC %

Clarus Therapeutics Holdings (Clarus Therapeutics Holdings) ROIC % : -97.58% (As of Jun. 2022)


View and export this data going back to 2021. Start your Free Trial

What is Clarus Therapeutics Holdings ROIC %?

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. Clarus Therapeutics Holdings's annualized return on invested capital (ROIC %) for the quarter that ended in Jun. 2022 was -97.58%.

As of today (2024-05-07), Clarus Therapeutics Holdings's WACC % is 0.00%. Clarus Therapeutics Holdings's ROIC % is 0.00% (calculated using TTM income statement data). Clarus Therapeutics Holdings earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Clarus Therapeutics Holdings ROIC % Historical Data

The historical data trend for Clarus Therapeutics Holdings's ROIC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Clarus Therapeutics Holdings ROIC % Chart

Clarus Therapeutics Holdings Annual Data
Trend Dec20 Dec21
ROIC %
-106.67 -88.14

Clarus Therapeutics Holdings Quarterly Data
Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22
ROIC % Get a 7-Day Free Trial - -79.73 -65.92 -123.40 -97.58

Competitive Comparison of Clarus Therapeutics Holdings's ROIC %

For the Drug Manufacturers - Specialty & Generic subindustry, Clarus Therapeutics Holdings's ROIC %, along with its competitors' market caps and ROIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Clarus Therapeutics Holdings's ROIC % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Clarus Therapeutics Holdings's ROIC % distribution charts can be found below:

* The bar in red indicates where Clarus Therapeutics Holdings's ROIC % falls into.



Clarus Therapeutics Holdings ROIC % Calculation

Clarus Therapeutics Holdings's annualized Return on Invested Capital (ROIC %) for the fiscal year that ended in Dec. 2021 is calculated as:

ROIC % (A: Dec. 2021 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Dec. 2020 ) + Invested Capital (A: Dec. 2021 ))/ count )
=-39.732 * ( 1 - 0% )/( (44.228 + 45.924)/ 2 )
=-39.732/45.076
=-88.14 %

where

Clarus Therapeutics Holdings's annualized Return on Invested Capital (ROIC %) for the quarter that ended in Jun. 2022 is calculated as:

ROIC % (Q: Jun. 2022 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Mar. 2022 ) + Invested Capital (Q: Jun. 2022 ))/ count )
=-42.608 * ( 1 - 0% )/( (41.909 + 45.417)/ 2 )
=-42.608/43.663
=-97.58 %

where

Note: The Operating Income data used here is four times the quarterly (Jun. 2022) data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Clarus Therapeutics Holdings  (OTCPK:CRXTQ) ROIC % Explanation

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROIC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Clarus Therapeutics Holdings's WACC % is 0.00%. Clarus Therapeutics Holdings's ROIC % is 0.00% (calculated using TTM income statement data).


Be Aware

Like ROE % and ROA %, ROIC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.


Clarus Therapeutics Holdings ROIC % Related Terms

Thank you for viewing the detailed overview of Clarus Therapeutics Holdings's ROIC % provided by GuruFocus.com. Please click on the following links to see related term pages.


Clarus Therapeutics Holdings (Clarus Therapeutics Holdings) Business Description

Traded in Other Exchanges
N/A
Address
555 Skokie Boulevard, Suite 340, Northbrook, IL, USA, 60062
Clarus Therapeutics Holdings Inc is a pharmaceutical company with expertise in developing androgen and metabolic therapies for men and women, including potential therapies for orphan indications. The company is focused on focused on the commercialization of JATENZO (testosterone undecanoate), the first and only oral testosterone replacement, or testosterone replacement therapy, and JATENZO is the sole source of company's revenue.
Executives
Thomas Mcnerney & Partners Lp 10 percent owner 45 S. 7TH ST., SUITE 3060, MINNEAPOLIS MN 55402
Kimberly M Murphy director 101 EAST KENNEDY BLVD., SUITE 2800, TAMPA FL 33602
Elizabeth Cermak director 1414 RALEIGH ROAD, SUITE 400, CHAPEL HILL NC 27517
Prygocki Mark A Sr director C/O MEDICS, 8125 N. HAYDEN RD, SCOTTSDALE AZ 85258
John Kenneth Amory director C/O CLARUS THERAPEUTICS HOLDINGS, INC., 555 SKOKIE BLVD, SUITE 340, NORTHBROOK IL 60662
Robert E. Dudley director, officer: Chief Executive Officer 555 SKOKIE BOULEVARD, SUITE 340, NORTHBROOK IL 60062
Joseph Hernandez director C/O MICROLIN BIO, INC., NEW YORK NY 10022
Richard D Peterson officer: Chief Financial Officer 1110 WEST COMMERCIAL BOULEVARD, FORT LAUDERDALE FL 33309
Frank Jaeger officer: Chief Commercial Officer CLARUS THERAPEUTICS HOLDINGS, INC., 555 SKOKIE BLVD, SUITE 340, NORTHBROOK IL 60662
Steven A. Bourne officer: Chief Administrative Officer 555 SKOKIE BOULEVARD, SUITE 340, NORTHBROOK IL 60062
Ffi Fund Ltd 10 percent owner DMS HOUSE, 20 GENESIS CLOSE, GRAND CAYMAN, GEORGE TOWN E9 KY1-1208
Thomas, Mcnerney & Partners Ii L.p. 10 percent owner 45 SOUTH 7TH STREET, SUITE 3060, Minneapolis MN 55402
Thomas, Mcnerney & Partners Ii, Llc 10 percent owner 45 SOUTH SEVENTH STREET, SUITE 3060, MINNEAPOLIS MN 55402
Tmp Nominee Ii, Llc 10 percent owner 45 SOUTH SEVENTH STREET, SUITE 3060, MINNEAPOLIS MN 55402
Tmp Associates Ii Lp 10 percent owner 45 SOUTH SEVENTH STREET, SUITE 3060, MINNEAPOLIS MN 55402

Clarus Therapeutics Holdings (Clarus Therapeutics Holdings) Headlines

From GuruFocus